Chin-LeeWuMDPhD

Pathology • Boston, MA

Genitourinary Pathology, Molecular Genetics, Anatomic Pathology, Clinical Pathology

Director, Genitourinary Pathology, Professor, Pathology-Massachusetts General Hospital, Harvard Medical School

Join to view full profile

Dr. Wu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wu's full profile

Already have an account?

Office
55 Fruit St
Pathology Associates Wrn 2
Boston, MA 02114
Phone+1 617-726-2967

Fax+1 617-726-7474

Summary

Dr. Chin-Lee Wu is a pathologist in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital and Newton-Wellesley Hospital. He received his medical degree from Southern Medical University and has been in practice 34 years. He specializes in genitourinary pathology, molecular genetics, anatomic pathology, and clinical pathology and is experienced in genitourinary pathology. He has more than 200 publications and over 15000 citings.

Education & Training

Massachusetts General HospitalResidency, Pathology-Anatomic and Clinical, 1995 - 1999
Southern Medical UniversityClass of 1983

Certifications & Licensure

MA State Medical License 1998 - 2027
American Board of Pathology Anatomic Pathology

Clinical Trials

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery Start of enrollment: 2008 Dec 01
Completed
Phase 2

Publications & Presentations

PubMed

Single-cell and spatial transcriptomics reveal a tumor-associated macrophage subpopulation that mediates prostate cancer progression and metastasis.
Shenglin Mei, Hanyu Zhang, Taghreed Hirz, Nathan Elias Jeffries, Yanxin Xu
Molecular Cancer Research. 2025-03-19
1 citations
Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma.
Jiao Li, Kaimeng Huang, Meha Thakur, Fiona McBride, Ananthan Sadagopan
Nature Metabolism. 2025-02-06
A Proposal for Revised and Simplified Renal Pelvic Urothelial Carcinoma Staging Criteria: A Clinicopathologic Study of 141 Tumors.
Miranda E Machacek, Hanzhang Wang, Kyle Devins, Peter M Sadow, Chin-Lee Wu
The American Journal of Surgical Pathology. 2025-02-01

Press Mentions

Gene-Expression Signature May Signify Risk for Recurrence, Metastasis in Prostate CancerApril 15th, 2013